Verve Therapeutics (VERV) Reports Q2 Loss, Lags Revenue Estimates

Verve Therapeutics (VERV) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of$ 0.68. This compares to loss of $0.87 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 13.24%. A quarter ago, it was expected that this biotechnology firm would post a loss of$ 0.68 per share when it actually produced a loss of $0.59, delivering a surprise of 13.24%. Over the last four quarters, the comp ...